Results 11 to 20 of about 579,519 (167)
The simultaneous occurrence of two primary tumors in one patient is not uncommon, but one tumor metastasizing to another malignancy is a rare phenomenon. Tumor-to-tumor metastasis was first described by Berent in 1902.
Renu Sukumaran +3 more
doaj +2 more sources
Although the Hox transcript antisense intergenic RNA (HOTAIR), a vital long non-coding RNA, is known to participate in the development and progression of a wide range of carcinomas, there are still no published reports regarding its expression in ...
Hui Zhang, Xianglin Meng
doaj +2 more sources
Cervical metastasis of esophagogastric junction cancer
As cervical metastases in esophagogastric junction cancer are extremely rare, the authors herein report a case. A 63-year-old woman presented with dysphagia since 6 months.
Zhiqiang Cai +3 more
doaj +2 more sources
Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction [PDF]
Background The epidermal growth factor receptor (EGFR) inhibitor, gefitinib, has been reported to successfully treat advanced non-small cell lung cancer patients with genetic mutations in EGFR.
Wang Wen-Ping +3 more
doaj +2 more sources
Portal vein tumor thrombosis (PVTT) with advanced gastric cancer is very rare; when it occurs, it exhibits aggressive growth and carries a poor prognosis. In addition, definitive treatment has not been established due to insufficient data.
Sung Don Oh +4 more
doaj +3 more sources
Breast Metastasis from Esophagogastric Junction Cancer: A Case Report [PDF]
Metastasis to breast from nonmammary malignancy is only about 1.3–2.7%. A few cases of squamous cell carcinoma of esophagus and adenocarcinoma of stomach metastasizing to breast have been reported, but this is probably the first report of breast ...
Sanghamitra Jena +4 more
doaj +2 more sources
Mixed adenoneuroendocrine carcinoma of the esophagogastric junction: a case report
Background Mixed adenoneuroendocrine carcinoma (MANEC) is a tumor of the gastrointestinal tract that contains both exocrine and endocrine components, with each component exceeding 30% of the total tumor area.
Miho Yamamoto +7 more
doaj +2 more sources
Perioperative FLOT versus Definitive 50.4 Gy Chemoradiotherapy in Siewert II Esophagogastric Junction Adenocarcinoma: A Multicenter Retrospective Cohort Study. [PDF]
Background: Optimal multimodal treatment for esophagogastric junction adenocarcinoma remains debated. While the ESOPEC trial supports perioperative FLOT, real-world evidence is limited, particularly for Siewert type II tumors.
Dinc Sonusen S +14 more
europepmc +2 more sources
How to decide surgical procedure for esophagogastric junction cancer? [PDF]
Standard surgical procedure for esophagogastric junction cancer, especially adenocarcinoma, has still remained controversial. Various procedures has been allowed and applied for Siewert type II tumors.
Yasuyuki Seto, Hiroharu Yamashita
doaj +1 more source
Background The prognosis of patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma is still dismal. There are no standard treatment strategies for these patients.
Xiaowen Liu +23 more
doaj +1 more source

